周四直播|2024 Year in Review

文摘   2024-12-09 17:46   江苏  

Why Attend this Event?

Topics of the webinar include Top trends in 2024, Review of key catalysts and major news, China for Global licensing boom, Prospects of 2025.



Event details

主题:BioVerse episode 16 - Asian Biotechies Walk Into BioVerse To Review 2024 in Biotech

时间: Dec 12th 2024, 8-9 PM BJT (Replay) / Dec 11th 2024, 12-1 PM ET(Live)

地点: zoom meeting(扫描二维码获得zoom注册链接或点击文末“阅读原文”)



Speakers intro

Angus Liu

Angus Liu is a deputy editor at Fierce Pharma, the go-to destination for the news and trends shaping the pharma industry. He leads the publication’s oncology coverage.

Jiamin ZhuoPhD

Jiamin is an accomplished professional with a diverse background spanning Ph.D. training, Wall Street equity research, and real-world commercial experience in both big pharma and small biotech. His journey includes roles as a business analyst at Decision Resource Group, catering to biopharma clients, and as an equity research associate at Guggenheim Invest Bank, delivering strategic insights to Wall Street investors. Jiamin has held various commercial positions at Takeda and bit.bio, a cell therapy biotech, where he played a crucial role in shaping commercial strategy for assets at various stages.


He is passionate about strategy development for drug candidates to optimize their potential for securing investors' funding, identifying BD opportunities, and ultimately achieving commercial success in the market. Currently, he serves as the Weekly Newsletter Editor and orchestrates the BioVerse Webinar at ISWT-community. Jiamin holds a BS degree from Peking University, a Ph.D. from Mayo Clinic, and postgraduate training at Boston University and MIT.


Leon ‘Jun’ Tang, PhD

(BioVerse webinar host)

Leon ‘Jun’ Tang, is the founding partner of InScienceWeTrust BioAdvisory, a business development company focused on the East-West cross-border partnerships in the pharmaceutical industry. Dr. Tang is also the founder of InScienceWeTrust Community, which has more than 2,000+ members from Asian biotech community. He is also the c-founder and host of Bioverse webinar.


Dr. Tang serves as a scientific advisor to Mianus Capital, a boutique US-based healthcare PE/VC fund currently focused on ophthalmology. He is also an advisor to BioSpark, an Asian biotech professional’s association based in Massachusetts.


Previously, Dr. Tang was a senior director of BD Search & Evaluation at Shanghai Henlius Biotech, a public biotech listed on Hong Kong Stock Exchange, a biotech sell-side analyst at Barclays Investment Bank, and a senior manager/senior analyst at the philanthropic venture fund of Cancer Research Institute of New York.


Dr. Tang has published 50+ academic papers, some of which are in Nature Reviews Drug Discovery, Lancet Oncology, Science Translational Medicine, Nature Communications, Science Advances, PNAS, etc. Dr. Tang received his bachelor’s degree from Tianjin University, master’s degree from Nankai University, PhD from Icahn School of Medicine of Mount Sinai, and postdoctoral training at Memorial Sloan Kettering Cancer Center.



Organizers



Partner &Collaborators



共建Biomedical创新生态圈!

如何加入BiG会员?

BiG生物创新社
Biomedical Innovation Group(BiG). To nurture an eco-system for biomedical innovation and imprint China on Global map.
 最新文章